The reaction catalyzed by carbamoyl phosphate synthetase I is the regulatory enzyme of the pathway
In rat with the treatment of 10 g/Kg/day BPC 157, the concentration of BPC 157 was estimated to be less than 1 g/ml in the blood which was too low to cause hypotension or hemodynamic change as demonstrated by the lack of vasodilation in the present study 6
Thats the real danger not BPC-157 itself, but whats in the vial

KG, 3 Department of Medical Sciences, Division of Gastroenterology, University of Turin, 4 The Texas Liver Institute, University of Texas Health San Antonio, and Arizona Liver Health, 5 Boehringer Ingelheim International GmbH, 6 Department of Internal Medicine II, Saarland University Medical Center, 7 National Institute for Health Research Biomedical Research Centre, University Hospital Birmingham, 8 Faculty of Medical Sciences, Newcastle University, 9 Covenant Metabolic Specialists, LLC, 10 Texas Liver Institute, University of Texas Health San Antonio, 11 The Institute of Cardiometabolism and Nutrition, Sorbonne Universit, Hpital PitiSalptrire, 12 Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 13 Boehringer Ingelheim Pharmaceuticals, Inc., 14 Virginia Commonwealth University Background: We evaluated non-invasive liver biomarkers from a phase II trial of survodutide, a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis
